Baloxavir-Based Combinations Delivered the Strongest Protection in a Lethal H5N1 Mouse Model
A lethal influenza A(H5N1) clade 2.3.4.4b challenge in mice has now put three familiar antivirals into direct competition: oseltamivir, baloxavir, and molnupiravir. The comparison matters because severe avian influenza can escalate quickly, and single-agent therapy may be asked to control a virus that is already replicating at high speed in the lung and, in some cases, spreading beyond it.
In this model, the advantage belonged most consistently to baloxavir-containing combinations. Those regimens produced complete survival, suppressed pulmonary replication to near the limit of detection, and prevented viral spread to the brain and heart.
Early Treatment Changed the Course of Infection
The experiment used 6- to 8-week-old female BALB/c mice infected intranasally with A/mink/Spain/3691–8_22VIR10586–10/2022 at 5 LD50 in a 50-µL inoculum. Treatment began at 6 hours postinfection, a deliberately early window that gives antivirals their best chance to blunt the first wave of replication before tissue injury and systemic dissemination become established.
Vehicle-treated mice lost weight rapidly and died uniformly. Against that backdrop, low-dose monotherapy produced only partial rescue. Oseltamivir and molnupiravir each yielded 2 of 7 survivors, while baloxavir produced 4 of 7 survivors and limited weight loss more consistently than either comparator.
The gap widened when combinations were tested. Across all three pairings—oseltamivir plus molnupiravir, baloxavir plus oseltamivir, and baloxavir plus molnupiravir—clinical trajectories improved, but the baloxavir-containing regimens stood out. At both dose pairs evaluated, those combinations achieved 7 of 7 survival through 18 days postinfection. The oseltamivir-molnupiravir pairing improved outcome, yet it did not match the completeness of protection seen with baloxavir in the mix.
Viral Suppression Extended Beyond the Lung
Survival alone would not tell the full story in a lethal influenza model. Tissue viral burden, especially outside the respiratory tract, offers a clearer read on whether treatment is truly containing infection or merely slowing it.
By day 4, baloxavir and oseltamivir monotherapy had already reduced lung titers, while molnupiravir had not shown the same early effect. Brain and heart titers were near or below the limit of detection at that stage, suggesting that dissemination had not yet fully taken hold. By day 6, the untreated mice carried high lung viral loads and detectable virus in both brain and heart. Under monotherapy, baloxavir controlled tissue infection most consistently and held brain and heart titers at the detection floor, while some mice receiving 25 mg/kg oseltamivir or molnupiravir still showed viral replication in the brain.
Combination therapy tightened that control further. Lung titers frequently approached the detection limit, especially in the baloxavir-containing arms, and systemic spread was largely abolished. The oseltamivir-molnupiravir combination also improved clearance and survival, but its lung antiviral effect remained weaker than the baloxavir-based regimens. In practical virologic terms, the addition of a second mechanism appears to have reduced the probability that residual replication could seed extra-pulmonary disease.
Pathology and Host Transcriptional Signals Moved in the Same Direction
Histopathology and immunohistochemistry at 6 days postinfection aligned with the virology. Vehicle-treated mice showed prominent influenza nucleoprotein staining in lung and brain, a visible marker of heavy tissue antigen burden in a lethal infection. Monotherapy reduced but did not eliminate that signal. Combination therapy drove it down much further, with the baloxavir-containing regimens producing the most consistent near-absence of nucleoprotein staining in both organs.
RNA sequencing added a mechanistic layer. Treated animals clustered apart from vehicle-treated animals on principal component analysis, and the baloxavir-containing combinations formed tighter clusters than monotherapy groups in both lung and brain. The transcriptional response was not merely quieter; it was biologically different. Pathway analysis showed reduced enrichment of innate immune, inflammatory, and type II interferon pathways in the combination arms, alongside relative preservation of neuronal and synaptic pathways, including cognition, memory, and vesicle-mediated transport. In a disease that can injure both the respiratory tract and the central nervous system, a treatment that suppresses viral replication while also dampening the downstream inflammatory cascade has a plausible advantage.
Why Baloxavir May Have Carried the Regimens
The findings fit the pharmacology. Baloxavir inhibits the viral cap-dependent endonuclease, a mechanism that blocks a critical step in influenza mRNA synthesis. Oseltamivir targets neuraminidase, limiting viral release, while molnupiravir introduces lethal mutagenesis through a nucleoside analog mechanism. In a rapidly progressive H5N1 infection, using two distinct antiviral pressures may narrow the virus’s room to escape and reduce the chance that a partially suppressed lung infection seeds the brain or heart.
Bliss-independence analysis supported that interpretation. The baloxavir-containing combinations showed positive interaction estimates for end-of-study survival, most clearly at the 20/25 mg/kg dose pairs. At the higher 20/50 mg/kg pairs, the positive interaction remained but was smaller, suggesting that the incremental benefit of combination therapy may diminish as antiviral exposure rises. The oseltamivir-molnupiravir pairing also showed a weaker, dose-dependent interaction.
What the Mouse Data Can and Cannot Support
Several limitations keep these results firmly in the preclinical category. Treatment began at 6 hours postinfection, much earlier than many patients present for care. Sample sizes for tissue titration were modest, and molnupiravir is not licensed for influenza. Exploratory single nucleotide polymorphism analysis of viral RNA from day 6 lung tissue did not identify canonical PA-I38 or NA-H275Y substitutions in treated groups, but targeted deep sequencing and phenotypic susceptibility testing were not performed.
The study also leaves delayed treatment unanswered. No 24-hour or 48-hour postinfection start was tested, so the degree to which baloxavir-based combinations would preserve their advantage after a clinically realistic delay remains unknown.
Even with those constraints, the signal across endpoints was consistent. Baloxavir-based combinations improved survival, lowered lung viral burden, and blocked extrapulmonary dissemination in a lethal H5N1 clade 2.3.4.4b model, making them the strongest candidates in this experiment for early preparedness planning when severe disease or resistance risk could undermine single-agent therapy.